The development of anti-amyloid therapy for Alzheimer's disease: From secretase modulators to polymerisation inhibitors

CNS Drugs

Volumn 19, Issue 12, 2005, Pages 989-996

  Aisen, Paul S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BRYOSTATIN 1; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CLIOQUINOL; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; GELSOLIN; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LY 450139; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHELATION; CLINICAL TRIAL; DISEASE COURSE; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; NERVE DEGENERATION; NONHUMAN; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; VACCINATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CHELATING AGENTS; ENDOPEPTIDASES; HUMANS; IMMUNOTHERAPY; POLYMERS; PROTEASE INHIBITORS;

EID: 28844456475     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519120-00002     Document Type: Review

References (64)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67
2. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
3. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24
4. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000; 924: 17-25
5. Petkova AT, Ishii Y, Balbach JJ, et al. A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 2002; 99: 16742-7
6. Iqbal K, Alonso Adel C, El-Akkad E, et al. Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays. J Mol Neurosci 2003; 20: 425-9
7. Samuel W, Terry RD, DeTeresa R, et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 1994; 51: 772-8
8. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7
9. Nash JM. Alzheimer's disease: new insights into its cause lead to new drug strategies. Time 2001; 157: 80-81, 85
10. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6
12. Lippa CF, Saunders AM, Smith TW, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996; 46: 406-12
13. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-70
14. Smith MA, Drew KL, Nunomura A, et al. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 2002; 40: 527-31
15. Davies P. A very incomplete comprehensive theory of Alzheimer's disease. Ann N Y Acad Sci 2000; 924: 8-16
16. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-32
17. Lopez-Toledano MA, Shelanski ML. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 2004; 24: 5439-44
18. Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003; 422: 438-41
19. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85
20. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-22
21. Milano J, McKay J, Dagenais C, et al. Modulation of Notch Processing by {gamma}-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-58
22. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-26
23. Netzer WJ, Dou F, Cai D, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 2003; 100: 12444-9
24. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6
25. Barten DM, Guss VL, Corsa JA, et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005 Feb; 312 (2): 635-43
26. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitors in volunteers. Clin Neuropharmacol 2005; 28: 126-32
27. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999; 402: 33-7
28. Vassar R, Bennett BD, Babu-Khan S, et al. beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41
29. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999; 402: 537-40
30. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999; 14: 419-27
31. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000; 290: 150-3
32. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta- secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317-24
33. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4: 231-2
34. Chang WP, Koelsch G, Wong S, et al. In vivo inhibition of A beta production by memopsin 2 (beta-secretase) inhibitors. J Neurochem 2004; 89: 1409-16
35. Stachel SJ, Coburn CA, Steele TG, et al. Structure-based design of potent and selective ceel-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 2004; 47: 6447-50
36. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters. Cancer Res 1988; 48: 1-8
37. Etcheberrigaray R, Tan M, Dewachter I, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A 2004; 101: 11141-6
38. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
39. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100: 2023-8
40. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54
41. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52
42. Gilman S, Koller M, Black RS, et al. Clinical effects of A beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 10: 1553-62
43. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002; 22: 7873-8
44. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-7
45. Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003; 14: 10-8
46. Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003; 23: 29-33
47. Ye C, Walsh DM, Selkoe DJ, et al. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 2004; 366: 320-5
48. Walsh DM, Klyubin I, Fadeeva JV, et al. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002; 30: 552-7
49. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9
50. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-8
51. Aisen PS, Mehran M, Poole R, et al. Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease [abstract]. Neurobiol Aging 2004; 25: 20
52. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003; 26: 207-14
53. Raman B, Ban T, Yamaguchi K, et al. Metal ion-dependent effects of clioquinol on the fibril growth of an anyloid beta peptide. J Biol Chem 2005; 280: 16157-62
54. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76
55. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-91
56. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000; 20 Suppl.: S20-4
57. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001; 8 Suppl. 1: 28-35
58. Gervais F. GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging 2004; 25: S11-2
59. Hilbich C, Kisters-Woike B, Reed J, et al. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol 1992; 228: 460-73
60. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2002; 2: 417-23
61. Klunk WE, Debnath ML, Koros AM, et al. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 1998; 63: 1807-14
62. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76-84
63. Sparks DL, Sabbagh MN, Connor DJ, et al. Benefits of atorvastatin in subjects with ALzheimer's disease. Circulation 2004; 11017: III-813
64. Hutter-Paier B, Huttunen HJ, Puglielli L, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004; 44: 227-38